{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000056","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.449602+00:00","generated_at":"2026-06-02T18:53:49.440383+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arvinas Q1 cash $1.17B, licenses ARV-766 to Novartis for $150M upfront","bullets":["Q1 2024 revenue $25.3M, down from $32.5M YoY; R&D expenses $84.3M vs $95.3M YoY.","Cash, equivalents and marketable securities $1,174.8M as of March 31, down $91.7M from year-end.","Licensed ARV-766 to Novartis for $150M upfront, up to $1.01B in milestones plus royalties.","Top-line data for vepdegestrant Phase 3 VERITAC-2 trial on track for 2H 2024.","Phase 1 trial initiated for ARV-102 (LRRK2 degrader) in neurodegenerative diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000056","json":"https://secwatch.observer/filing/0001655759-24-000056.json","markdown":"https://secwatch.observer/filing/0001655759-24-000056.md","text":"https://secwatch.observer/filing/0001655759-24-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000056/0001655759-24-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000056/arvn-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:53:49.440383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"765241f9b390c919bd3a58784a1fb3aa0c588963","claim":"ARVINAS, INC. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 7, 2024 , Arvinas, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000056/0001655759-24-000056-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}